CSF2 and coronary artery disorder: randomized 21 patients who did not meet the CABG criteria but had coronary heart disease who were treated with an IC injection of 40 mg GM‐CSF or placebo and subcutaneous GM‐CSF (10 mg/kg) or placebo respectively for 2 weeks.